“Indication-specific pricing” (ISP) is an approach that linking a drug's price to the benefit of the drug in each of its approved indications. The Drug Pricing Lab proposes several approaches that facilitate ISP implementation.
Together with Mark Trusheim of MIT Sloan School of Management and Preston Atteberry, MD, the Drug Pricing Lab team articulated why biosimilars are not and will not effectively lower the price of biologic drugs after the period of market exclusivity.
Preston J. Atteberry, Peter B. Bach, Jennifer A. Ohn, Mark R. Trusheim
Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.